Side-by-side comparison of AI visibility scores, market position, and capabilities
Unilever, whole body deodorant launch 2024, MotionSense technology, parent €60.5B revenue 2024, men's deodorant leader
Degree is a personal care brand owned by Unilever, originally launched in 1990 in the United States under the mission of delivering protection that keeps pace with active lifestyles. The brand was built around MotionSense technology — a microencapsulation system embedded in the deodorant formula that releases additional freshness-active ingredients in direct response to physical movement and body heat, providing increased protection precisely when protection is most needed. This responsive delivery mechanism became a defining product innovation that differentiated Degree from static deodorant formulas and established it as a performance-oriented choice for active consumers.\n\nDegree's product line spans antiperspirant and deodorant sticks, dry sprays, clinical-strength formulas, and a rapidly expanding whole body deodorant category launched in 2024 — products designed to address underarm odor protection in non-traditional body areas as consumer hygiene norms evolve. The brand operates across men's and women's segments, with Degree Men as one of the leading men's deodorant franchises in the US market. Degree also maintains a partnership program with Paralympic and adaptive athletes, embedding its active credentials with inclusive positioning that resonates across a broad consumer base.\n\nDegree is part of Unilever's personal care division, which contributes to Unilever's €60.5 billion total revenue in 2024. Within the US men's deodorant category, Degree Men holds market leadership alongside Old Spice, competing on performance credentials and broad retail distribution across mass, drug, and grocery channels. The brand's 2024 expansion into whole body deodorant reflects a broader market shift toward full-body freshness solutions and positions Degree to capture incremental volume in a category it helped define.
a2z Radiology AI raised $20M in 2025 for its whole-body AI that simultaneously screens for 24+ conditions across CT scans — from incidental cancers to cardiovascular risk — in a single automated read.
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disease, aortic aneurysm, bone density loss, and organ abnormalities. The AI acts as a second reader that radiologists can use to catch incidental findings that fall outside the primary reason for a scan — a major source of missed diagnoses.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.